– ISRAEL, Tel Aviv – Biobeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, announced the appointment of Ray Cohen as its Chairman of the Board of Directors.
About Raymond W. Cohen
Ray Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of life science industry experience. He was the co-founder and CEO of publicly traded Axonics, Inc., a global leader in implantable neuromodulation devices that completed its initial public offering in late 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America, and was acquired by Boston Scientific in November 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical-stage renal denervation company, led the sale of SoniVie to Boston Scientific for $600 million.
Ray Cohen serves on the boards of several public and venture capital-backed innovative healthcare companies, including Kestra Medical Technologies (Nasdaq: KMTS); InspireMD (Nasdaq: NSPR); RxSight (Nasdaq: RXST), privately held Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice-chairman, and Spectrum Vascular as an independent director.
Ray Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners.
About Biobeat Technologies, Ltd
Biobeat, based in Israel with offices in Boca Raton Florida, is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp02, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM systems, Biobeat offers a small, unobtrusive “patch” device with enhanced patient comfort, especially during sleep, while collecting and transmitting real-time data to a mobile app. Biobeat’s products are 510(k) cleared by the US Food & Drug Administration.
For more information: https://www.bio-beat.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.